| Home | Log In | Register | Our Services | My Account | Contact | Help |
Biofrontera AG (B8F)
dreamcatcher
- 03 Jun 2014 20:31
Biofrontera AG is a biopharmaceutical company specializing on the development of drugs and medicinal cosmetics for the treatment of skin diseases and the regenerative care of damaged skin.
In February 2012 Biofrontera launched the prescription drug Ameluz® for the treatment of actinic keratosis on the German market. In other European countries Ameluz® is marketed through various local representatives. Ameluz® is applied in Photodynamic Therapy requiring a powerful source of red light. For this Biofrontera has developed the BF-RhodoLED® lamp, which was CE marked in November 2012.
As a cosmeceutical product Biofrontera markets Belixos® creme for the regenerative care of reddened and inflamed skin. It is Biofrontera’s intention to develop a line of cosmeceutical products for damaged skin under the Belixos brand.
Biofrontera AG operates as an administrative holding company with four wholly-owned subsidiaries, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH and Biofrontera Neuroscience GmbH. While the first two cover the operational business of Biofrontera group, the latter allow structured funding of individual clinical development projects. The companies occupy fully equipped, modern lab facilities with sufficient space for growth, an own GMP-certified laboratory and a GMP-certified medicament storage room.
Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the current CEO, and is located in Leverkusen, Germany.
Since 2006 Biofrontera is listed in the regulatory market under the ISIN DE0006046113, the company currently employs 35 people.
http://www.biofrontera.com/en/
Bullshare
- 08 Oct 2015 10:32
- 26 of 26
Shares Investor Evenings showcase up to four presentations from leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsWednesday 4th November 2015
Venue:Novotel Tower Bridge, London EC3N, 10 Pepys Street, London, EC3N 2NR
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Prof. Dr. Hermann Lübbert, CEO - Biofrontera (B8F) + More to be announced | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | We specialize in dermatology, because the health of your skin is our profession. With our innovative products we would like to cure and protect your skin, while creating value for our investors. Biofrontera AG operates as an administrative holding company with four wholly-owned subsidiaries, Biofrontera Bioscience GmbH, Biofrontera Pharma GmbH, Biofrontera Development GmbH and Biofrontera Neuroscience GmbH. While the first two cover the operational business of Biofrontera group, the latter allow structured funding of individual clinical development projects. The companies occupy fully equipped, modern lab facilities with sufficient space for growth, an own GMP-certified laboratory and a GMP-certified medicament storage room.Biofrontera group was founded in 1997 by Prof. Dr. Hermann Lübbert, the current CEO, and is located in Leverkusen, Germany. Since 2006 Biofrontera is listed in the regulatory market under the ISIN DE0006046113, the company currently employs 46 people. |
 | Magnolia Petroleum plc is an AIM quoted oil and gas production company focused on the acquisition, exploitation and development of oil and gas properties primarily located onshore in the United States. Led by a highly skilled management team with over 100 years combined experience in the onshore oil and gas industry, the Company already has interests in approximately 183+ producing properties and over 13,500 net mineral acres in two major project areas, the potentially game-changing and highly productive Bakken shale in North Dakota and the proven Woodford/Mississippi and Hunton formations in Oklahoma. |
- Page:
- 1
- 2
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Follow us on Twitter